Clinical trials: Application Site Wound
Surgical Site Infection
Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™
The purpose of this pilot study is to evaluate antimicrobial properties of a single test product, a vehicle product and a reference product applied in two different areas when used as a patient preoperative skin preparation.
- Trial name
- ZX-ZP-0035 (NCT02221232)
- Testing
- Chloraprep, ZuraPrep, ZuraPrep Vehicle
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Zurex Pharma, Inc.
Cicatrix, Wound-healing
Investigation Into the Safety and Scar-improvement Efficacy of Intradermal Juvidex Dosed Once or Three Times
The purpose of this study was to investigate the scar-improvement efficacy of three doses of intradermal Juvidex given once only or three times in male and female subjects and to collect further safety and tolerability data for…
- Trial name
- NCT00984516
- Testing
- Juvidex
- Where
- United Kingdom
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Renovo
Lung Cancer, Lung Cancer Metastatic
ANET Electrosurgery Applicator Pilot Evaluation Study
Evaluate the preliminary safety and performance of the Electrosurgery Applicator (ANET device) during and after bronchoscopic ablation of a target pulmonary nodule/tumor.
- Trial name
- NCT03400748
- Testing
- RF Ablation
- Where
- 4 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Olympus Corporation of the Americas
Surgical Site Infection
Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle
ZuraPrep is being evaluated for efficacy as a preoperative skin preparation solution to demonstrate its immediate and persistent antimicrobial properties.
- Trial name
- NCT02578771
- Testing
- ZuraPrep with 70% IPA, ZuraPrep without 70% IPA, ChloraPrep CHG/IPA Teal Tint
- Where
- United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Zurex Pharma, Inc.
No Protrusion, No Open Wound
The Sponsor Assigns Test Products to Six Skin Areas According to a Concealed Randomization Schedule; Neither the Evaluating Physicians Nor the Participants Know Which Product is Applied to Which Site, Preventing Bias.
This is a single-center, double-blind, randomized, and controlled study. The sponsor keeps the allocation of products to the six test sites confidential.
- Conditions
- No Protrusion, No Open Wound, No Severe Allergic Reaction, No Scar
- Trial name
- NCT07154004
- Testing
- Test Serum 897222 210, Test Serum 897222 212, Test Serum 897250 39
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BEIJING YUANBEN INFORMATION CONSULTING CO., LTD
Surgical Site Infection
Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™ (ZX-ZP-0055)
This is a randomized, paired-comparisons design where each subject receives two of the planned treatments.
- Trial name
- NCT02296645
- Testing
- ZuraPrep, ChloraPrep
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Zurex Pharma, Inc.
Surgical Site Infection
Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA
This is a safety study to determine the skin sensitization potential of ZuraPrep™ and ZuraPrep™ without isopropyl alcohol (IPA) after repetitive patch applications to skin of human subjects.
- Trial name
- NCT02160587
- Testing
- Chloraprep, 0.9% Physiological Saline, ZuraPrep without IPA
- Where
- United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Zurex Pharma, Inc.
Wound of Skin
Evaluation of the SPINNER Device for the Application of Wound Dressing: Treatment of Split Skin Graft Donor Sites
Evaluation of safety and performance of the SPINNER device and wound dressing in the treatment of donor-site wounds (DSW)
- Trial name
- SPINNER01 (NCT02680106)
- Testing
- SPINNER, JELONET / IBU Biatain
- Where
- 5 sites in Israel
- Volunteers
- 41 people
- Sponsor
- Nanomedic Technologies Ltd.
Burns, Traumatic Lesions
Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting
The purpose of this study is to determine the haemostatic efficacy of TT-173, reducing the bleeding time in the donor site of skin grafting.
- Trial name
- EHTIC (NCT02012569)
- Testing
- TT-173
- Where
- Spain
- Volunteers
- 78 people
- Sponsor
- Thrombotargets Europe S.L
Bacterial Infection
Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites
This study evaluates the safety and clinical benefit of MBN-101 administered intraoperatively to osteosynthesis or osteomyelitis sites for patients diagnosed with an orthopedic infection, with or without orthopaedic hardware.
- Trial name
- NCT02436876
- Testing
- MBN-101
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Microbion Corporation
Surgical Site Infection
Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA
This is a safety study to determine the cumulative skin irritation potential of ZuraPrep™ and ZuraPrep™ without Isopropyl Alcohol after repetitive patch applications to skin of human subjects.
- Trial name
- NCT02160574
- Testing
- ChloraPrep, 0.1% Sodium Lauryl Sulfate, 0.9% Physiological Saline
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Zurex Pharma, Inc.
Metastatic Solid Tumors, Stage 4 Cancer
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System.
- Trial name
- NCT07224464
- Testing
- The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New Phase Ltd.